Eloralintide (LY3841136)

Best Price Available

Overview

Eloralintide is an amylin analog developed by Eli Lilly and Company for weight management, given as a once-weekly subcutaneous injection. It is a 37 amino acid peptide containing three non-coded residues and a C20 fatty diacid that binds albumin, which is what stretches its action out to a week (PMID: 41109426). It is investigational everywhere. No regulator has approved it, and it is in phase 3 trials as of 2026. Amylin is a hormone released from pancreatic beta cells alongside insulin. It slows gastric emptying, suppresses glucagon after meals and signals meal termination through the brainstem. Pramlintide, the first approved amylin analog, proved the concept but was limited by frequent dosing and modest effect. The newer analogs split into two groups: dual amylin and calcitonin receptor agonists such as cagrilintide, and selective amylin receptor agonists. Eloralintide belongs to the second group. In cells expressing human receptors it activated the amylin 1 receptor about 12-fold more potently than the calcitonin receptor and about 11-fold more potently than the amylin 3 receptor (PMID: 41109426). That selectivity is the design idea, because calcitonin receptor engagement is thought to contribute to nausea. Preclinical results back this up. In lean rats, eloralintide produced significantly less conditioned taste avoidance than cagrilintide, a marker of aversive signaling. In diet-induced obese rats it reduced food intake and lowered body weight in a dose-dependent way, mostly through loss of fat mass, and pharmacokinetics in rats and monkeys supported weekly dosing (PMID: 41109426). The human data are what make this compound notable. A phase 1 single-ascending-dose study in 48 healthy participants reported mostly mild adverse events and week 4 weight reduction of 2.5 percent and 4.4 percent in the two highest single-dose groups against a 0.6 percent gain on placebo (NCT05295940, PMID: 41109426). A 12-week multiple-ascending-dose study in 100 participants with obesity or overweight, run without dose escalation, reported weight reduction across dose groups ranging from 2.6 percent to 11.3 percent, with decreased appetite in 19 percent, headache in 12 percent and fatigue in 11 percent, and infrequent gastrointestinal events: diarrhea in 10 percent, nausea in 8 percent and vomiting in 4 percent (PMID: 41559929). A 48-week phase 2 trial randomized 263 adults across six dose or dose-escalation arms and placebo and reported mean weight change from baseline of about 9 percent to 20 percent against 0.4 percent on placebo, with nausea and fatigue the most common adverse events (NCT06230523, PMID: 41207310). A network meta-analysis of six trials in 4642 adults ranked high-dose eloralintide second only to amycretin for percent body weight reduction, ahead of semaglutide, while noting that gastrointestinal adverse events rose with high doses of amylin-based therapies and that the evidence is still sparse and low certainty (PMID: 42175595). Anything sold outside a trial is not the studied product and has no verified identity or purity.

Potential Research Fields

Contraindications

Research Disclaimer

This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

$179.99

$17.9990

1

1

vial

Sign in to leave a review

Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Eloralintide (LY3841136).

Tracking since Sep 7, 2026 · 1 data point

Best Price